Overview
LAEKNA-B (2105)
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic dise...
- Open
- 6.500
- High
- 6.780
- Low
- 6.300
- Prev. Close
- 6.760
- Volume
- 1.09M
- Turnover
- 7.24M
- Avg Price
- 6.628
- Bid/Ask Ratio
- 33.33%
- Amplitude
- 7.10%
- 52wk High
- 19.360
- Volume Ratio
- 0.93
- Turnover Ratio
- 0.24%
- 52wk Low
- 5.295
- HK Mkt Cap
- 2.99B
- Market CapHKD
- 2.99B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.260
- EPSDynamic
- -0.0130
- EPSStatic
- --
- BVPS
- 3.05
- P/B
- 2.17
- HK Shares
- 452.06M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 452.06M
- Min lot size
- 500
- Currency
- HKD
LAEKNA-B Analyst Rating
View moreForecast & Rating
Aug 26, 2026- Strong buy66.67%
- Buy33.33%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 2
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Jul, 3
Laekna Inc. rose sharply today, closing at HKD 7.800, up 6.70% from the previous close, with a turnover of HKD 15.1 million and a turnover rate of 0.44%. The stock gained momentum in the afternoon session, hitting an intraday high of HKD 7.850 after a low of HKD 7.330, forming a low-open high-go pattern. Q3 2025 revenue surged 24,927.84% YoY to HKD 55.9 million, but net loss narrowed only 11.11% to HKD 54.5 million, with EPS at -HKD 0.1353. Despite the losses, the stock price remains well below its 52-week high, and the market's focus on its pipeline progress drove the rally. However, the net profit margin remains deeply negative at -97.53%, underscoring the company's pre-revenue stage.
- Jul, 2
来凯医药今日放量上涨 9.7%,收报 7.37 港元,主因公司披露最高达 5600 万港元的场内股份回购计划,由董事长吕向阳及主要股东等内部人士支持,直接提振市场信心。盘中走势呈探底回升:上午盘一度从 7.13 港元开盘后冲高至 7.45 港元,但随即回落至 6.9 港元日内低点,下午盘逐步回升至收盘高位,全天成交额 4604 万港元,为近期较活跃水平。股价当前仍较 52 周高点 20.9 港元下跌 65%,YTD 跌幅 45.8%,且处于 20 日均线 8.23 港元和 60 日均线 12.64 港元之下,价格位置偏弱。财报方面,Q4 2025 营业收入达 5683 万港元,同比大增超 264 倍,净亏损收窄至 5542 万港元,EPS 亏损 0.14 港元同比改善 15.9%,基本面边际改善。此外,公司近期授予 Vasque Bio LAE118 的大中华区外全球权益,产品管线持续推进。不过,公司仍处于研发阶段尚无商业化产品,且近期高管秘书有人员变动。
News
Market Movers · LAEKNA falls 7% in Hong Kong trading
Weekly Review · Weekly Recap | LAEKNA-B +5.13%, obesity pipeline advances
prnewswire · Obesity Week 2026 | Laekna Announces Poster Presentation on LAE124, an Internally Discovered Oral Small-Molecule Amylin Receptor Agonist
PUBT · Laekna's Oral Obesity Drug LAE124 Reduces Body Weight in Rat Studies
Market Movers · LAEKNA climbs 6% as LAE103 completes Phase I study
Market Movers · LAEKNA climbs 7% as LAE103 completes Phase I trial
